Accelerating access for all through research and innovation in immunization: Recommendations from Strategic Priority 7 of the Immunization Agenda 2030

被引:0
|
作者
Sarley, David [1 ]
Hwang, Angela
Hall, B. Fenton [2 ]
Ford, Andrew [2 ]
Giersing, Birgitte [3 ]
Kaslow, David C. [4 ]
Wahl, Brian [5 ,6 ]
Friede, Martin
机构
[1] Bill & Melinda Gates Fdn, Seattle, WA USA
[2] NIAID, Div Microbiol & Infect Dis, NIH, Bethesda, MD USA
[3] World Hlth Org, Geneva, Switzerland
[4] PATH, Seattle, WA USA
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Baltimore, MD USA
[6] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
基金
比尔及梅琳达.盖茨基金会;
关键词
Vaccines; Research; Innovation; IA2030; VACCINES; VACCINATION; COUNTRIES;
D O I
10.1016/j.vaccine.2022.11.041
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Research and innovation have been fundamental to many of the successes in immunization thus far, and will play important roles in the future success of Immunization Agenda 2030 (IA2030). Strategic Priority 7 (SP7) of IA2030, which addresses research and innovation, is explicitly informed by country needs and priorities, and aims to strengthen the innovation ecosystem through capacity building and collaboration at country, regional, and global levels. SP7 identifies four key focus areas: (1) ''needs-based innovation", (2) ''new and improved products, services, and practices", (3) ''evidence for implementation", and (4) ''local capacity". Strategic interventions in these key focus areas apply the lessons of the Global Vaccine Action Plan and the ''Decade of Vaccines" to emphasize local innovation, promote the use of research by countries to improve program performance and impact, and encourage capacity building for the development and implementation of innovations. The proposed approach will maintain a focus on the development of new vaccines and the improvement of existing vaccines, and increase attention to innovation in service delivery. Monitoring and evaluation will foster evidence-based priority setting at the country level and help to ground the global research and development (R&D) agenda in the needs of communities. Together, these approaches are intended to harness the power of research and innovation more effectively, to meet the challenges of the future and achieve the ambitious goals of IA2030. (c) 2024 World Health Organization; licensee Elsevier Ltd. This is an open access article under the CC BY IGO license. (http://creativecommons.org/licenses/by/3.0/igo/).
引用
收藏
页码:S82 / S90
页数:9
相关论文
共 7 条
  • [1] Building and sustaining public and political commitment to the value of vaccination: Recommendations for the Immunization Agenda 2030 (Strategic Priority Area 2)
    Olayinka, Folake
    Sauer, Molly
    Menning, Lisa
    Summers, Diane
    Wonodi, Chizoba
    Mackay, Susan
    MacDonald, Noni E.
    Figueroa, J. Peter
    Andriamitantsoa, Benjamin
    Bonsu, George
    Haldar, Pradeep
    Lindstrand, Ann
    Shimp, Lora
    VACCINE, 2024, 42 : S43 - S53
  • [2] Innovative vaccine research through the lens of implementation science: fulfilling the strategic goals of the Immunization Agenda 2030
    Kangning Sheng
    Kan Chen
    Yingqi Chen
    Linchen Chu
    Chenlu Fan
    Chuanxi Fu
    BMC Global and Public Health, 3 (1):
  • [3] Accelerating into Immunization Agenda 2030 with momentum from China's successful COVID-19 vaccination campaign during dynamic COVID Zero
    Rodewald, Lance E.
    INFECTIOUS DISEASES OF POVERTY, 2023, 12 (01)
  • [4] Accelerating into Immunization Agenda 2030 with momentum from China’s successful COVID-19 vaccination campaign during dynamic COVID Zero
    Rodewald Lance E
    贫困所致传染病(英文), 2023, 12 (05)
  • [5] Accelerating into Immunization Agenda 2030 with momentum from China’s successful COVID-19 vaccination campaign during dynamic COVID Zero
    Lance E. Rodewald
    Infectious Diseases of Poverty, 12
  • [6] Towards a single European strategic research and innovation agenda on materials for all reactor generations through dedicated projects
    Malerba, Lorenzo
    Agostini, Pietro
    Angiolini, Massimo
    Bertolus, Marjorie
    EPJ NUCLEAR SCIENCES & TECHNOLOGIES, 2022, 8
  • [7] Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030
    Hasso-Agopsowicz, Mateusz
    Hwang, Angela
    Hollm-Delgado, Maria-Graciela
    Umbelino-Walker, Isis
    Karron, Ruth A.
    Rao, Raman
    Asante, Kwaku Poku
    Sheel, Meru
    Sparrow, Erin
    Giersing, Birgitte
    EBIOMEDICINE, 2024, 110